A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
ملخص الخبر
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
تابع أحدث أخبار المصادر الموثوقة مع ملخصات موجزة. افتح رابط المصدر الأصلي للتفاصيل.